A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation
Figure 4
The Kaplan-Meier estimates of biopsy-confirmed acute rejection in (a) all subjects converted to sirolimus (), (b) subjects converted during the first posttransplant year (), and (c) subjects converted later after transplant (). Lines indicate principal treatment regimen: SRL ± MMF (solid line); SRL + CsA (dotted line); SRL + TAC (dashed line). There were no significant differences between treatment combinations.